The European Medicines Evaluation Committee gave a positive opinion on admitting Rasonque to the market for people with metastatic pancreatic cancer, following a trial involving 500 patients. The medicine may extend patients’ lives and could become available on the Dutch market.

There have so far been few treatment options for these patients.